Sorafenib (BAY 43-9006) slows cell cycle progression, is a TRAIL sensitizer,but is not a radiosensitizer

被引：0
|
作者：
Plastaras, John P.
Soto, Nanette M.
Dicker, David T.
Flaherty, Keith T.
Smith, Charles D.
El-Deiry, Wafik S.
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] Drexel Univ, Coll Med, Philadelphia, PA 19104 USA
[3] Penn State Coll Med, Hershey, PA USA
来源：
CANCER RESEARCH | 2006年 / 66卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3828
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Role of BAY 43-9006 in combination with temozolomide and melphalan in metastatic melanoma
    Yoo, J
    Augustine, CK
    Yoshimoto, Y
    Petersen, RP
    Pruitt, SK
    Ali-Osman, F
    Tyler, DS
    ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (02) : 12 - 12
  • [32] Prospective study of positron emission tomography evaluating the activity of sorafenib (BAY 43-9006) in patients with advanced tumors.
    Kawada, K
    Murakami, K
    Sato, T
    Kojima, Y
    Ebi, H
    Kitagawa, K
    Kim, Y
    Araki, K
    Mukai, H
    Tahara, M
    Nakajima, H
    Nakajima, K
    Minami, H
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9062S - 9062S
  • [33] Phase II study of BAY 43-9006 (sorafenib) in patients with chemo-naive hormone refractory prostate cancer
    Akyol, F.
    Ozyigit, G.
    Selek, U.
    Onal, C.
    Karabulut, E.
    Ozen, H.
    EJC SUPPLEMENTS, 2005, 3 (02): : 248 - 249
  • [34] Sorafenib (BAY 43-9006) inhibits the growth and angiogenesis of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.
    Kim, S
    Yazici, YD
    Calzada, G
    Wang, ZY
    Younes, MN
    Jasser, SA
    Myers, JN
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8967S - 8967S
  • [35] Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
    Yong S. Chang
    Jalila Adnane
    Pamela A. Trail
    Joan Levy
    Arris Henderson
    Dahai Xue
    Elizabeth Bortolon
    Marina Ichetovkin
    Charles Chen
    Angela McNabola
    Dean Wilkie
    Christopher A. Carter
    Ian C. A. Taylor
    Mark Lynch
    Scott Wilhelm
    Cancer Chemotherapy and Pharmacology, 2007, 59 : 561 - 574
  • [36] Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models
    Chang, Yong S.
    Adnane, Jalila
    Trail, Pamela A.
    Levy, Joan
    Henderson, Arris
    Xue, Dahai
    Bortolon, Elizabeth
    Ichetovkin, Marina
    Chen, Charles
    McNabola, Angela
    Wilkie, Dean
    Carter, Christopher A.
    Taylor, Ian C. A.
    Lynch, Mark
    Wilhelm, Scott
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2007, 59 (05) : 561 - 574
  • [37] Pharmacodynamic study of BAY 43-9006 in patients with renal cell carcinoma (RCQ) and melanoma.
    Flaherty, KT
    Tuveson, DA
    Brose, MS
    Rosen, MA
    Lee, RJ
    Schwartz, B
    Schuchter, LM
    O'Dwyer, PJ
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6089S - 6089S
  • [38] Randomised phase-III-study of the multi-kinase inhibitors Sorafenib (BAY 43-9006) for patients with advanced renal cell carcinoma
    Staehler, M.
    Siebels, M.
    Stief, C.
    Jaeger, E.
    Heinzer, H.
    Grimm, M. -O.
    Gschwend, J.
    Wirth, M.
    Michell, M. -S.
    Rohde, D.
    Krause, S.
    Siegsmund, M.
    Scheuring, U.
    Schwartz, B.
    Escudier, B.
    ONKOLOGE, 2007, 13 : 18 - 19
  • [39] Randomized Phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC)
    Escudier, B.
    Szczylik, C.
    Eisen, T.
    Oudard, S.
    Stadler, W. M.
    Schwartz, B.
    Shan, M.
    Bukowski, R. M.
    EJC SUPPLEMENTS, 2005, 3 (02): : 226 - 226
  • [40] Phase II trial of sorafenib (BAY 43-9006) in combination with interferon alpha 2b in patients with metastatic renal cell carcinoma
    Gollob, J. A.
    Moran, K.
    Richmond, T.
    Jones, J. M.
    Baell, T. E.
    Rathmell, W. K.
    Peterson, B. L.
    EJC SUPPLEMENTS, 2005, 3 (02): : 226 - 227
12345